Treatment outcome of superficial leiomyosarcoma.
dermal
leiomyosarcoma
outcome
subcutaneous
superficial
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
02
09
2020
revised:
29
09
2020
accepted:
05
10
2020
pubmed:
17
10
2020
medline:
12
1
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
Nonuterine leiomyosarcomas (LMS) are common extremity soft-tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS. We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean age and follow-up were 57 ± 15 and 7 ± 5 years. Depth was classified as dermal (based in the skin; n = 35, 43%) and subcutaneous (based below the dermis, above the fascia; n = 47, 57%) on the final resection specimen. Dermal cases were treated with negative margin resection, while subcutaneous tumors were evaluated by a multidisciplinary team for consideration of possible adjuvant therapy. The 10-year disease-specific survival (DSS) for superficial LMS was 90% with no difference (p = .18) in the 10-year DSS between patients with dermal (100%) and subcutaneous (86%) LMS. All disease recurrences occurred in subcutaneous LMS (17% vs. 0%, p = .02) and subcutaneous tumors had a worse10-year metastatic free survival (81% vs. 100%, p = .03). The results of this study suggest that dermal LMS can be managed with a negative margin resection alone. Although the prognosis for patients with subcutaneous LMS is quite favorable, there is some risk for local and distant recurrence, and such patients will benefit from multidisciplinary care.
Sections du résumé
BACKGROUND
BACKGROUND
Nonuterine leiomyosarcomas (LMS) are common extremity soft-tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS.
METHODS
METHODS
We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean age and follow-up were 57 ± 15 and 7 ± 5 years. Depth was classified as dermal (based in the skin; n = 35, 43%) and subcutaneous (based below the dermis, above the fascia; n = 47, 57%) on the final resection specimen. Dermal cases were treated with negative margin resection, while subcutaneous tumors were evaluated by a multidisciplinary team for consideration of possible adjuvant therapy.
RESULTS
RESULTS
The 10-year disease-specific survival (DSS) for superficial LMS was 90% with no difference (p = .18) in the 10-year DSS between patients with dermal (100%) and subcutaneous (86%) LMS. All disease recurrences occurred in subcutaneous LMS (17% vs. 0%, p = .02) and subcutaneous tumors had a worse10-year metastatic free survival (81% vs. 100%, p = .03).
CONCLUSIONS
CONCLUSIONS
The results of this study suggest that dermal LMS can be managed with a negative margin resection alone. Although the prognosis for patients with subcutaneous LMS is quite favorable, there is some risk for local and distant recurrence, and such patients will benefit from multidisciplinary care.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
127-132Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Duffaud FR-C I, Salas S, Pautier P. Recent advances in understanding and managing leiomyosarcomas. F1000Prime Rep. 2015;7:55.
Hall BG AH, Webber NP, Ward RA, et al. Atypical intradermal smooth muscle neoplasms (formerly cutaneous leiomyosarcomas): case series, immunohistochemical profile and review of the literature. Appl Immunohistochem Mol Morphol. 2013;21(2):132-138.
Francescutti V, Sanghera SS, Cheney RT, et al. Homogenous good outcome in a heterogeneous group of tumors: an institutional series of outcomes of superficial soft tissue sarcomas. Sarcoma. 2015;2015:325049-7.
Rydholm A, Gustafson P, Rooser B, Willen H, Berg N. Subcutaneous sarcomas. J Bone Jt Surg. 1991;73-B(4):662-667.
Svarvar C, Böhling T, Berlin Ö, et al. Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer. 2007;109(2):282-291.
Starling J, 3rd, Coldiron BM. Mohs micrographic surgery for the treatment of cutaneous leiomyosarcoma. J Am Acad Dermatol. 2011;64(6):1119-1122.
Kraft S, Fletcher CDM. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous “leiomyosarcoma”. Am J Surg Pathol. 2011;35:599-607.
Massi D, Franchi A, Alos L, et al. Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases. Histopathology. 2010;56(2):251-262.
Aneiros-Fernandez J, Antonio Retamero J, Husein-Elahmed H, Ovalle F, Aneiros-Cachaza J. Primary cutaneous and subcutaneous leiomyosarcomas: evolution and prognostic factors. Eur J Dermatol. 2016;26(1):9-12.
Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350-362.
Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;286:241-246.
Salemis N. Recurrent subcutaneous trunk leiomyosarcoma: management and review of the literature. J Nat Sci Biol Med. 2013;4(1):238-242.
Lang R. Malignant tumors of the dermis and subcutaneous tissue. Textbook of Dermatologic Surgery. Piccin Nuova Libraria; 2008:435-470.
Fields JP, Helwig EB. Leiomyosarcoma of the skin and subcutaneous tissue. Cancer. 1981;47:156-169.
Stout AP, Hill WT. Leiomyosarcoma of the superficial soft tissues. Cancer. 1958;11:844-854.
Pisters PWT, Pollock RE, Lewis VO, et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg. 2007;246(4):675-681.
Salas S, Stoeckle E, Collin F, et al. Superficial soft tissue sarcomas (S-STS): a study of 367 patients from the French Sarcoma Group (FSG) database. Eur J Cancer. 2009;45(12):2091-2102.
Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679-1689.
Winchester DS, Hocker TL, Brewer JD, et al. Leiomyosarcoma of the skin: clinical, histopathologic, and prognostic factors that influence outcomes. J Am Acad Dermatol. 2014;71(5):919-925.
Deneve JL, Messina JL, Bui MM, et al. Cutaneous Leiomyosarcoma: treatment and outcomes with a standardized margin of resection. Cancer Control. 2013;20(4):307-312.
Micheli A, Mariotto A, Giorgi Rossi A, Gatta G, Muti P. The prognostic role of gender in survival of adult cancer patients. EUROCARE Working Group. Eur J Cancer. 1998;34(14 Spec No):2271-2278.
Laitinen MK, Albergo JI, Stevenson JD, et al. Female gender in the hormonally active age group plays a major role in high-grade chondrosarcoma survival. Acta Oncol. 2020;59(2):242-246.
Houdek MT, Walczak BE, Wilke BK, Kakar S, Rose PS, Shin AY. What factors influence the outcome of surgically treated soft tissue sarcomas of the hand and wrist? Hand. 2017;12(5):493-500.
Wascher RL MY. Recurrent cutaneous leiomyosarcoma. Cancer. 1992;70(2):490-492.
Traub F, Griffin AM, Wunder JS, Ferguson PC. Influence of unplanned excisions on the outcomes of patients with stage III extremity soft-tissue sarcoma. Cancer. 2018;124(19):3868-3875.
Nandra R, Forsberg J, Grimer R. If you lump is bigger than a golf ball and growing, think Sarcoma. Eur J Cancer Surg. 2015;41:1400-1405.
Venkatesan M, Richards CJ, McCulloch TA, Perks AGB, Raurell A, Ashford RU. Inadvertent surgical resection of soft tissue sarcomas. Eur J Surg Oncol. 2012;38(4):346-351.